Early Stage Glycosylation Biomarkers in Alzheimer’s Disease

Patricia Regan, Paula L. McClean, Thomas Smyth, Margaret Doherty

Research output: Contribution to journalArticle

Abstract

Alzheimer’s disease (AD) is of great cause for concern in our ageing population, which currently lacks diagnostic tools to permit accurate and timely diagnosis for affected individuals. The development of such tools could enable therapeutic interventions earlier in the disease course and thus potentially reducing the debilitating effects of AD. Glycosylation is a common, and important, post translational modification of proteins implicated in a host of disease states resulting in a complex array of glycans being incorporated into biomolecules. Recent investigations of glycan profiles, in a wide range of conditions, has been made possible due to technological advances in the field enabling accurate glycoanalyses. Amyloid beta (Aβ) peptides, tau protein, and other important proteins involved in AD pathogenesis, have altered glycosylation profiles. Crucially, these abnormalities present early in the disease state, are present in the peripheral blood, and help to distinguish AD from other dementias. This review describes the aberrant glycome in AD, focusing on proteins implicated in development and progression, and elucidates the potential of glycome aberrations as early stage biomarkers of AD.
Original languageEnglish
Article number92
JournalNatural Medicines
Volume6
Issue number3
DOIs
Publication statusPublished - 3 Sep 2019
Externally publishedYes

Fingerprint

Glycosylation
Biomarkers
Alzheimer Disease
Polysaccharides
tau Proteins
Amyloid beta-Peptides
Post Translational Protein Processing
Dementia
Proteins
Biomolecules
Aberrations
Amyloid
Blood
Aging of materials
Population
Peptides

Cite this

Regan, Patricia ; McClean, Paula L. ; Smyth, Thomas ; Doherty, Margaret. / Early Stage Glycosylation Biomarkers in Alzheimer’s Disease. In: Natural Medicines. 2019 ; Vol. 6, No. 3.
@article{5d2435e05c1548aaa30e95475d28623a,
title = "Early Stage Glycosylation Biomarkers in Alzheimer’s Disease",
abstract = "Alzheimer’s disease (AD) is of great cause for concern in our ageing population, which currently lacks diagnostic tools to permit accurate and timely diagnosis for affected individuals. The development of such tools could enable therapeutic interventions earlier in the disease course and thus potentially reducing the debilitating effects of AD. Glycosylation is a common, and important, post translational modification of proteins implicated in a host of disease states resulting in a complex array of glycans being incorporated into biomolecules. Recent investigations of glycan profiles, in a wide range of conditions, has been made possible due to technological advances in the field enabling accurate glycoanalyses. Amyloid beta (Aβ) peptides, tau protein, and other important proteins involved in AD pathogenesis, have altered glycosylation profiles. Crucially, these abnormalities present early in the disease state, are present in the peripheral blood, and help to distinguish AD from other dementias. This review describes the aberrant glycome in AD, focusing on proteins implicated in development and progression, and elucidates the potential of glycome aberrations as early stage biomarkers of AD.",
keywords = "Alzheimer's, Biomarker, Glycosylation, Aβ, Tau",
author = "Patricia Regan and McClean, {Paula L.} and Thomas Smyth and Margaret Doherty",
year = "2019",
month = "9",
day = "3",
doi = "10.3390/medicines6030092",
language = "English",
volume = "6",
journal = "Natural Medicines",
issn = "1340-3443",
publisher = "Springer Verlag",
number = "3",

}

Early Stage Glycosylation Biomarkers in Alzheimer’s Disease. / Regan, Patricia; McClean, Paula L.; Smyth, Thomas; Doherty, Margaret.

In: Natural Medicines, Vol. 6, No. 3, 92, 03.09.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Early Stage Glycosylation Biomarkers in Alzheimer’s Disease

AU - Regan, Patricia

AU - McClean, Paula L.

AU - Smyth, Thomas

AU - Doherty, Margaret

PY - 2019/9/3

Y1 - 2019/9/3

N2 - Alzheimer’s disease (AD) is of great cause for concern in our ageing population, which currently lacks diagnostic tools to permit accurate and timely diagnosis for affected individuals. The development of such tools could enable therapeutic interventions earlier in the disease course and thus potentially reducing the debilitating effects of AD. Glycosylation is a common, and important, post translational modification of proteins implicated in a host of disease states resulting in a complex array of glycans being incorporated into biomolecules. Recent investigations of glycan profiles, in a wide range of conditions, has been made possible due to technological advances in the field enabling accurate glycoanalyses. Amyloid beta (Aβ) peptides, tau protein, and other important proteins involved in AD pathogenesis, have altered glycosylation profiles. Crucially, these abnormalities present early in the disease state, are present in the peripheral blood, and help to distinguish AD from other dementias. This review describes the aberrant glycome in AD, focusing on proteins implicated in development and progression, and elucidates the potential of glycome aberrations as early stage biomarkers of AD.

AB - Alzheimer’s disease (AD) is of great cause for concern in our ageing population, which currently lacks diagnostic tools to permit accurate and timely diagnosis for affected individuals. The development of such tools could enable therapeutic interventions earlier in the disease course and thus potentially reducing the debilitating effects of AD. Glycosylation is a common, and important, post translational modification of proteins implicated in a host of disease states resulting in a complex array of glycans being incorporated into biomolecules. Recent investigations of glycan profiles, in a wide range of conditions, has been made possible due to technological advances in the field enabling accurate glycoanalyses. Amyloid beta (Aβ) peptides, tau protein, and other important proteins involved in AD pathogenesis, have altered glycosylation profiles. Crucially, these abnormalities present early in the disease state, are present in the peripheral blood, and help to distinguish AD from other dementias. This review describes the aberrant glycome in AD, focusing on proteins implicated in development and progression, and elucidates the potential of glycome aberrations as early stage biomarkers of AD.

KW - Alzheimer's

KW - Biomarker

KW - Glycosylation

KW - Aβ

KW - Tau

UR - http://www.mendeley.com/research/early-stage-glycosylation-biomarkers-alzheimers-disease

U2 - 10.3390/medicines6030092

DO - 10.3390/medicines6030092

M3 - Article

VL - 6

JO - Natural Medicines

JF - Natural Medicines

SN - 1340-3443

IS - 3

M1 - 92

ER -